IN2014MN02106A - - Google Patents

Download PDF

Info

Publication number
IN2014MN02106A
IN2014MN02106A IN2106MUN2014A IN2014MN02106A IN 2014MN02106 A IN2014MN02106 A IN 2014MN02106A IN 2106MUN2014 A IN2106MUN2014 A IN 2106MUN2014A IN 2014MN02106 A IN2014MN02106 A IN 2014MN02106A
Authority
IN
India
Prior art keywords
compound
formula
disclosed
preparation
pharmaceutically acceptable
Prior art date
Application number
Inventor
Fabio E S Souza
Alena Rudolph
Ming Pan
Boris Gorin
Teng Ko Ngooi
Jason A Bexrud
Ricardo Orprecio
Huzaifa Rangwala
Original Assignee
Alphora Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alphora Res Inc filed Critical Alphora Res Inc
Publication of IN2014MN02106A publication Critical patent/IN2014MN02106A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Abstract

Disclosed is a compound of formula (1) or a pharmaceutically acceptable salt thereof where R R R R R R R R R R R R R and R are as disclosed herein. Also disclosed is a process for the preparation of the compound of formula 1 or a pharmaceutically acceptable salt thereof and5 intermediates used therein. The compound of formula (1) can be used in the preparation of halichondrin analogs such as Eribulin; and a process for its preparation from the compound of formula (1) is also disclosed.
IN2106MUN2014 2012-03-30 2013-03-28 IN2014MN02106A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261618004P 2012-03-30 2012-03-30
US201261647127P 2012-05-15 2012-05-15
PCT/CA2013/050254 WO2013142999A1 (en) 2012-03-30 2013-03-28 Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein

Publications (1)

Publication Number Publication Date
IN2014MN02106A true IN2014MN02106A (en) 2015-09-11

Family

ID=49258019

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2106MUN2014 IN2014MN02106A (en) 2012-03-30 2013-03-28

Country Status (8)

Country Link
US (2) US9278979B2 (en)
EP (1) EP2831082B1 (en)
JP (1) JP6531911B2 (en)
CN (1) CN104334562A (en)
AU (1) AU2013239290B2 (en)
CA (1) CA2868627C (en)
IN (1) IN2014MN02106A (en)
WO (1) WO2013142999A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5226304B2 (en) 2004-06-03 2013-07-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 Intermediates for the preparation of halichondrin B analogues
CN101883763B (en) 2007-10-03 2016-04-20 卫材R&D管理有限公司 For the synthesis of intermediate and the method for halichondrin b analogs
BR112012018232B8 (en) 2010-01-26 2023-01-10 Eisai R&D Man Co Ltd FURO [3,2-B] PYRAN DERIVATIVE COMPOUNDS USEFUL IN THE SYNTHESIS OF HALICONDRIN B ANALOGS AND ER-80402 AND ERIBULIN SYNTHESIS METHODS
WO2013078559A1 (en) 2011-11-30 2013-06-06 Alphora Research Inc. Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene
CA2857395A1 (en) 2011-12-16 2013-06-20 Alphora Research Inc. Process for preparation of 3-((2s,5s)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives and intermediates useful thereof
EP2797945B1 (en) 2011-12-29 2016-03-16 Alphora Research Inc. 2-((2s,3s,4r,5r)-5-((s)-3-amino-2-hydroxyprop-1-yl)-4-methoxy-3-(phenylsulfonylmethyl)tetrahydrofuran-2-yl)acetaldehyde derivatives and process for their preparation
CA2916537C (en) 2013-07-03 2021-07-27 Alphora Research Inc. Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein including intermediates containing -so2-(p-tolyl) groups
CN103483352A (en) * 2013-10-18 2014-01-01 李友香 Medicinal bulk drug for resisting tumors
BR112016009452B1 (en) * 2013-11-04 2022-06-07 Eisai R&D Management Co., Ltd Methods of preparing intermediates in the synthesis of eribulin, methods of preparing eribulin and eribulin mesylate, and intermediate compounds
ES2723355T3 (en) 2013-12-06 2019-08-26 Eisai R&D Man Co Ltd Useful methods in the synthesis of halicondrine B analogues
TW201617326A (en) 2014-03-06 2016-05-16 Ａｌｐｈｏｒａ研發股份有限公司 Crystalline derivatives of (S)-1-((2R,3R,4S,5S)-5-allyl-3-methoxy-4-(tosylmethyl)tetrahydrofuran-2-yl)-3-aminopropan-2-ol
JP2017520586A (en) 2014-06-30 2017-07-27 プレジデント アンド フェローズ オブ ハーバード カレッジ Synthesis and use of halichondrin analogues
CN105713031B (en) * 2014-12-05 2021-05-07 正大天晴药业集团股份有限公司 Intermediate for preparing eribulin and preparation method thereof
WO2016176560A1 (en) 2015-04-30 2016-11-03 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
US10308661B2 (en) 2015-05-07 2019-06-04 Eisai R&D Management Co., Ltd. Macrocyclization reactions and intermediates and other fragments useful in the synthesis of halichondrin macrolides
MX2018009794A (en) 2016-02-12 2018-12-17 Eisai R&D Man Co Ltd Intermediates in the synthesis of eribulin and related methods of synthesis.
KR102445255B1 (en) 2016-03-02 2022-09-22 에자이 알앤드디 매니지먼트 가부시키가이샤 Eribulin-Based Antibody-Drug Conjugates and Methods of Use
BR112018074287A2 (en) * 2016-05-26 2019-06-18 Dr Reddys Laboratories Ltd process for preparing eribulin and intermediates thereof
CN114805322A (en) 2016-06-30 2022-07-29 卫材R&D管理有限公司 Prins reactions and intermediates useful for the synthesis of halichondrin macrolides and analogs thereof
JP6978758B2 (en) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ Palladium-mediated ketolization
WO2018096478A2 (en) 2016-11-23 2018-05-31 Dr. Reddy’S Laboratories Limited Process for preparation of eribulin and intermediates thereof
CN108658956B (en) * 2017-03-28 2021-02-02 上海时莱生物技术有限公司 Eribulin intermediate and preparation method thereof
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
EP3606928B1 (en) 2017-04-05 2022-09-07 President and Fellows of Harvard College Macrocyclic compound and uses thereof
CN108948064B (en) * 2017-05-17 2021-02-02 上海时莱生物技术有限公司 Eribulin intermediate and preparation method thereof
WO2018217894A1 (en) * 2017-05-24 2018-11-29 Eisai R&D Management Co., Ltd. Fluorine-labelled halichondrin derivatives and related methods of synthesis
IL307273A (en) 2017-07-06 2023-11-01 Harvard College Synthesis of halichondrins
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
WO2019099646A1 (en) 2017-11-15 2019-05-23 President And Fellows Of Harvard College Macrocyclic compounds and uses thereof
JP7469226B2 (en) * 2018-01-03 2024-04-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 The Prins reaction and compounds useful for the synthesis of halichondrin macrolides and their analogues
CN114213429B (en) * 2021-12-22 2023-06-20 苏州正济药业有限公司 Preparation method of methanesulfonic acid Ai Li brin impurity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436238A (en) 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
US5338865A (en) 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
ATE251133T1 (en) 1993-07-09 2003-10-15 Theramex NEW STRUCTURAL VITAMIN D DERIVATIVES
EP2277873B1 (en) * 1998-06-17 2012-05-30 Eisai R&D Management Co., Ltd. Intermediate compound for the preparation of halichondrin analogs
US7001982B2 (en) 2003-03-31 2006-02-21 Council Of Scientific And Industrial Research Non-natural C-linked carbo-β-peptides with robust secondary structures
JP5226304B2 (en) 2004-06-03 2013-07-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 Intermediates for the preparation of halichondrin B analogues
US20060045846A1 (en) * 2004-08-30 2006-03-02 Horstmann Thomas E Reagents and methods for labeling terminal olefins
MX2010010902A (en) * 2008-04-04 2010-12-21 Eisai R&D Man Co Ltd Halichondrin b analogs.
WO2013078559A1 (en) 2011-11-30 2013-06-06 Alphora Research Inc. Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene
CA2857395A1 (en) 2011-12-16 2013-06-20 Alphora Research Inc. Process for preparation of 3-((2s,5s)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives and intermediates useful thereof
EP2797945B1 (en) * 2011-12-29 2016-03-16 Alphora Research Inc. 2-((2s,3s,4r,5r)-5-((s)-3-amino-2-hydroxyprop-1-yl)-4-methoxy-3-(phenylsulfonylmethyl)tetrahydrofuran-2-yl)acetaldehyde derivatives and process for their preparation
WO2014183211A1 (en) 2013-05-15 2014-11-20 Alphora Research Inc. 3-((2s,5s)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives, their preparation and intermediates useful thereof

Also Published As

Publication number Publication date
CA2868627C (en) 2021-02-16
WO2013142999A1 (en) 2013-10-03
AU2013239290B2 (en) 2017-08-03
CN104334562A (en) 2015-02-04
EP2831082B1 (en) 2019-02-20
AU2013239290A1 (en) 2014-10-30
CA2868627A1 (en) 2013-10-03
EP2831082A1 (en) 2015-02-04
US20160152631A1 (en) 2016-06-02
JP2015512897A (en) 2015-04-30
JP6531911B2 (en) 2019-06-19
US9278979B2 (en) 2016-03-08
US20150065733A1 (en) 2015-03-05
US9695187B2 (en) 2017-07-04
EP2831082A4 (en) 2016-01-06

Similar Documents

Publication Publication Date Title
IN2014MN02106A (en)
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
MX2016006336A (en) Pyrazolopyrimidine compounds.
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
IN2014MN01521A (en)
IN2014MN02598A (en)
AU2012214029A8 (en) Rorgammat inhibitors
UA110354C2 (en) Anti-viral compounds
PH12014502040A1 (en) Heterocyclyl compounds
TN2011000400A1 (en) Inhibitors of beta-secretase
NZ729037A (en) Carboxylic acid compound, method for preparation thereof, and use thereof
MY175854A (en) Novel quinolone derivatives
EA201491362A1 (en) ANESTHYZING COMPOUNDS AND METHODS OF THEIR APPLICATION
IN2014MN02459A (en)
IN2014CN04530A (en)
CR20200286A (en) Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
IN2015DN01119A (en)
MX2014007897A (en) New azetidine derivatives, pharmaceutical compositions and uses thereof.
PH12016500885A1 (en) Novel heterocyclic compounds
PH12016500394A1 (en) Polymorphic form of pyrrole derivative and intermediate thereof
MD20160105A2 (en) 2-Amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides
MX364400B (en) Tetracycline compounds.
IN2012DN02502A (en)
MX2013008340A (en) Novel 4-amino-n-hydroxy-benzamides as hdac inhibitors for the treatment of cancer.
IN2014CN04449A (en)